Cargando…

Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients

Tumor escape is often associated with abnormalities in the surface expression of the human leukocyte antigen class I (HLA-I) antigens thereby limiting CD8(+) cytotoxic T cell responses. This impaired HLA-I surface expression can be mediated by deficient expression of components of the antigen proces...

Descripción completa

Detalles Bibliográficos
Autores principales: Lazaridou, Maria-Filothei, Gonschorek, Evamaria, Massa, Chiara, Friedrich, Michael, Handke, Diana, Mueller, Anja, Jasinski-Bergner, Simon, Dummer, Reinhard, Koelblinger, Peter, Seliger, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458634/
https://www.ncbi.nlm.nih.gov/pubmed/32923135
http://dx.doi.org/10.1080/2162402X.2020.1774323
_version_ 1783576238943633408
author Lazaridou, Maria-Filothei
Gonschorek, Evamaria
Massa, Chiara
Friedrich, Michael
Handke, Diana
Mueller, Anja
Jasinski-Bergner, Simon
Dummer, Reinhard
Koelblinger, Peter
Seliger, Barbara
author_facet Lazaridou, Maria-Filothei
Gonschorek, Evamaria
Massa, Chiara
Friedrich, Michael
Handke, Diana
Mueller, Anja
Jasinski-Bergner, Simon
Dummer, Reinhard
Koelblinger, Peter
Seliger, Barbara
author_sort Lazaridou, Maria-Filothei
collection PubMed
description Tumor escape is often associated with abnormalities in the surface expression of the human leukocyte antigen class I (HLA-I) antigens thereby limiting CD8(+) cytotoxic T cell responses. This impaired HLA-I surface expression can be mediated by deficient expression of components of the antigen processing and presentation machinery (APM) due to epigenetic, transcriptional and/or post-transcriptional processes. Since a discordant mRNA and protein expression pattern of APM components including the peptide transporter associated with antigen processing 1 (TAP1) has been frequently described in tumors of distinct origin, a post-transcriptional control of APM components caused by microRNAs (miR) was suggested. Using an in silico approach, miR-200a-5p has been identified as a candidate miR binding to the 3ʹ untranslated region (UTR) of TAP1. Luciferase reporter assays demonstrated a specific binding of miR-200a-5p to the TAP1 3ʹ-UTR. Furthermore, the miR-200a-5p expression is inversely correlated with the TAP1 protein expression in HEK293T cells and in a panel of melanoma cell lines as well as in primary melanoma lesions. High levels of miR-200a-5p expression were associated with a shorter overall survival of melanoma patients. Overexpression of miR-200a-5p reduced TAP1 levels, which was accompanied by a decreased HLA-I surface expression and an enhanced NK cell sensitivity of melanoma cells. These data show for the first time a miR-mediated control of the peptide transporter subunit TAP1 in melanoma thereby leading to a reduced HLA-I surface expression accompanied by an altered immune recognition and reduced patients’ survival. ABBREVIATIONS: Ab: antibody; ACTB: β-actin; APM: antigen processing and presentation machinery; ATCC: American tissue culture collection; β(2)-m: β(2)-microglobulin; BSA: bovine serum albumin; CTL: cytotoxic T lymphocyte; FCS: fetal calf serum; FFL: firefly luciferase; FFPE: formalin-fixed paraffin-embedded; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; HC: heavy chain; HLA: human leukocyte antigen; HLA-I: HLA class I; HRP: horseradish peroxidase; IFN: interferon; im-miR: immune modulatory miRNA; LMP: low molecular weight protein; luc: luciferase; MFI: mean fluorescence intensity; MHC: major histocompatibility complex; miR: microRNA; NC: negative control; NK: natural killer; NSCLC: non-small cell lung carcinoma; OS: overall survival; PBMC: peripheral blood mononuclear cells; RBP: RNA-binding proteins; RL: Renilla; RLU: relative light units; TAP: transporter associated with antigen processing; tpn: tapasin; UTR: untranslated region.
format Online
Article
Text
id pubmed-7458634
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-74586342020-09-11 Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients Lazaridou, Maria-Filothei Gonschorek, Evamaria Massa, Chiara Friedrich, Michael Handke, Diana Mueller, Anja Jasinski-Bergner, Simon Dummer, Reinhard Koelblinger, Peter Seliger, Barbara Oncoimmunology Original Research Tumor escape is often associated with abnormalities in the surface expression of the human leukocyte antigen class I (HLA-I) antigens thereby limiting CD8(+) cytotoxic T cell responses. This impaired HLA-I surface expression can be mediated by deficient expression of components of the antigen processing and presentation machinery (APM) due to epigenetic, transcriptional and/or post-transcriptional processes. Since a discordant mRNA and protein expression pattern of APM components including the peptide transporter associated with antigen processing 1 (TAP1) has been frequently described in tumors of distinct origin, a post-transcriptional control of APM components caused by microRNAs (miR) was suggested. Using an in silico approach, miR-200a-5p has been identified as a candidate miR binding to the 3ʹ untranslated region (UTR) of TAP1. Luciferase reporter assays demonstrated a specific binding of miR-200a-5p to the TAP1 3ʹ-UTR. Furthermore, the miR-200a-5p expression is inversely correlated with the TAP1 protein expression in HEK293T cells and in a panel of melanoma cell lines as well as in primary melanoma lesions. High levels of miR-200a-5p expression were associated with a shorter overall survival of melanoma patients. Overexpression of miR-200a-5p reduced TAP1 levels, which was accompanied by a decreased HLA-I surface expression and an enhanced NK cell sensitivity of melanoma cells. These data show for the first time a miR-mediated control of the peptide transporter subunit TAP1 in melanoma thereby leading to a reduced HLA-I surface expression accompanied by an altered immune recognition and reduced patients’ survival. ABBREVIATIONS: Ab: antibody; ACTB: β-actin; APM: antigen processing and presentation machinery; ATCC: American tissue culture collection; β(2)-m: β(2)-microglobulin; BSA: bovine serum albumin; CTL: cytotoxic T lymphocyte; FCS: fetal calf serum; FFL: firefly luciferase; FFPE: formalin-fixed paraffin-embedded; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; HC: heavy chain; HLA: human leukocyte antigen; HLA-I: HLA class I; HRP: horseradish peroxidase; IFN: interferon; im-miR: immune modulatory miRNA; LMP: low molecular weight protein; luc: luciferase; MFI: mean fluorescence intensity; MHC: major histocompatibility complex; miR: microRNA; NC: negative control; NK: natural killer; NSCLC: non-small cell lung carcinoma; OS: overall survival; PBMC: peripheral blood mononuclear cells; RBP: RNA-binding proteins; RL: Renilla; RLU: relative light units; TAP: transporter associated with antigen processing; tpn: tapasin; UTR: untranslated region. Taylor & Francis 2020-06-03 /pmc/articles/PMC7458634/ /pubmed/32923135 http://dx.doi.org/10.1080/2162402X.2020.1774323 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Lazaridou, Maria-Filothei
Gonschorek, Evamaria
Massa, Chiara
Friedrich, Michael
Handke, Diana
Mueller, Anja
Jasinski-Bergner, Simon
Dummer, Reinhard
Koelblinger, Peter
Seliger, Barbara
Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients
title Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients
title_full Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients
title_fullStr Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients
title_full_unstemmed Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients
title_short Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients
title_sort identification of mir-200a-5p targeting the peptide transporter tap1 and its association with the clinical outcome of melanoma patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458634/
https://www.ncbi.nlm.nih.gov/pubmed/32923135
http://dx.doi.org/10.1080/2162402X.2020.1774323
work_keys_str_mv AT lazaridoumariafilothei identificationofmir200a5ptargetingthepeptidetransportertap1anditsassociationwiththeclinicaloutcomeofmelanomapatients
AT gonschorekevamaria identificationofmir200a5ptargetingthepeptidetransportertap1anditsassociationwiththeclinicaloutcomeofmelanomapatients
AT massachiara identificationofmir200a5ptargetingthepeptidetransportertap1anditsassociationwiththeclinicaloutcomeofmelanomapatients
AT friedrichmichael identificationofmir200a5ptargetingthepeptidetransportertap1anditsassociationwiththeclinicaloutcomeofmelanomapatients
AT handkediana identificationofmir200a5ptargetingthepeptidetransportertap1anditsassociationwiththeclinicaloutcomeofmelanomapatients
AT muelleranja identificationofmir200a5ptargetingthepeptidetransportertap1anditsassociationwiththeclinicaloutcomeofmelanomapatients
AT jasinskibergnersimon identificationofmir200a5ptargetingthepeptidetransportertap1anditsassociationwiththeclinicaloutcomeofmelanomapatients
AT dummerreinhard identificationofmir200a5ptargetingthepeptidetransportertap1anditsassociationwiththeclinicaloutcomeofmelanomapatients
AT koelblingerpeter identificationofmir200a5ptargetingthepeptidetransportertap1anditsassociationwiththeclinicaloutcomeofmelanomapatients
AT seligerbarbara identificationofmir200a5ptargetingthepeptidetransportertap1anditsassociationwiththeclinicaloutcomeofmelanomapatients